Stocks › SBFM
Sunshine Biopharma Inc.
SBFM·Nasdaq·
United States·USD
$2.23
-0.12 (-5.11%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
SBFM
Sunshine Biopharma Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
SBFMS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of SBFM by members of U.S. Congress · 1 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Roger WilliamsHouse · R · TX |
SBFMSunshine Biopharma Inc. · Stock |
Purchase $1,001 - $15,000 |
Jun 12, 2024 | Jun 30, 2022 | Filing ↗ |
Whale Activity
Position changes in SBFM reported for 2026-09-30 by 16 institutional filers
- Increased3
- New5
- Held4
- Decreased0
- Closed2
- No prior filing2
| Filer | Shares | Value | Change |
|---|---|---|---|
| JANE STREET GROUP, LLC | 60.3K | $47K | increased |
| UBS Group AG | 34.7K | $27K | new |
| Virtu Financial LLC | 22.2K | $17K | new |
| XTX Topco Ltd | 20.2K | $16K | new |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 18.4K | $14K | new |
| Pinnacle Financial Group, Inc. | 1,200 | $928 | — |
| MORGAN STANLEY | 385 | $298 | held |
| SBI Securities Co., Ltd. | 213 | $165 | increased |
| Caitong International Asset Management Co., Ltd | 50 | $39 | increased |
| Robinhood Markets, Inc. | 39 | $30 | — |
| JPMORGAN CHASE & CO | 8 | $6 | new |
| NATIONAL BANK OF CANADA /FI/ | 5 | $4 | held |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by SBFM insiders, by quarter · Form 4
No open-market insider buys or sells in the last two years.
Recent Insider Transactions
55 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| NATAN DAVIDDirector | Grant / award | +58.3K | $0.00 | $0 | Aug 7, 2026 | Form 4 ↗ |
| NATAN DAVIDDirector | Grant / award | +100.0K | $0.00 | $0 | Apr 14, 2026 | Form 4 ↗ |
| Slilaty Steve N.Chief Executive Officer · Director · 10% owner | Purchase | +100.0K | $0.10 | $10K | Mar 4, 2024 | Form 4 ↗ |
| Slilaty Steve N.Chief Executive Officer · Director · 10% owner | Purchase | +20.0K | n/c | — | Feb 8, 2024 | Form 4 ↗ |
| Sebaaly CamilleCFO/Secretary | Purchase | +30.0K | $0.76 | $23K | Nov 30, 2022 | Form 4 ↗ |
| Sebaaly CamilleCFO/Secretary | Purchase | +25.0K | $1.22 | $31K | Jun 3, 2022 | Form 4 ↗ |
| Slilaty Steve N.Chief Executive Officer · Director | Disposition to issuer | −990.0K | $0.10 | $99K | Feb 18, 2022 | Form 4 ↗ |
| MERZOUKI ABDERRAZZAKChief Operating Officer · Director | Grant / award | +20.0M | $0.00 | $0 | Jan 6, 2021 | Form 4 ↗ |
| Slilaty Steve N.Chief Executive Officer · Director | Grant / award | +20.0M | $0.00 | $0 | Jan 6, 2021 | Form 4 ↗ |
| Sebaaly CamilleCFO/Secretary · Director | Grant / award | +20.0M | $0.00 | $0 | Jan 6, 2021 | Form 4 ↗ |
| Slilaty Steve N.Chief Executive Officer · Director | Grant / award | +500.0K | $0.10 | $50K | Jun 17, 2020 | Form 4 ↗ |
| Sebaaly CamilleCFO/Secretary · Director | Grant / award | −323.7K | $0.00 | $0 | Dec 31, 2019 | Form 4 ↗ |
| Slilaty Steve N.Chief Executive Officer · Director | Other | +323.7K | $0.00 | $0 | Dec 31, 2019 | Form 4 ↗ |
| Sebaaly CamilleCFO/Secretary · Director | Grant / award | +1.3M | $0.00 | $0 | Dec 19, 2019 | Form 4 ↗ |
| MERZOUKI ABDERRAZZAKChief Operating Officer · Director | Grant / award | +1.3M | $0.00 | $0 | Dec 19, 2019 | Form 4 ↗ |
| Slilaty Steve N.Chief Executive Officer · Director | Grant / award | +1.3M | $0.00 | $0 | Dec 19, 2019 | Form 4 ↗ |
| Sebaaly CamilleCFO/Secretary · Director | Grant / award | +1.1M | $0.00 | $0 | Oct 20, 2019 | Form 4 ↗ |
| MERZOUKI ABDERRAZZAKChief Operating Officer · Director | Grant / award | +1.1M | $0.00 | $0 | Oct 20, 2019 | Form 4 ↗ |
| Slilaty Steve N.Chief Executive Officer · Director | Grant / award | +1.1M | $0.00 | $0 | Oct 20, 2019 | Form 4 ↗ |
| Sebaaly CamilleCFO/Secretary · Director | Grant / award | +550.0K | $0.00 | $0 | Sep 11, 2019 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding SBFM · SEC Form N-PORT
No mutual fund or ETF has reported SBFM in an N-PORT filing in the last seven months.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Intracoastal Capital LLCSCHEDULE 13G/A · passive (13G) · 430.3K shares10.0%
Nov 10, 2026 · ↗ - Daniel B. AsherSCHEDULE 13G/A · passive (13G) · 430.3K shares10.0%
Nov 10, 2026 · ↗ - Mitchell P. KopinSCHEDULE 13G/A · passive (13G) · 430.3K shares10.0%
Nov 10, 2026 · ↗ - BJI Financial GroupSCHEDULE 13G · passive (13G) · 909.9K shares6.0%
Oct 14, 2026 · ↗ - Heights Capital Management, Inc.SCHEDULE 13G · passive (13G) · 1.6M shares9.9%
Oct 13, 2026 · ↗ - CVI Investments, Inc.SCHEDULE 13G · passive (13G) · 1.6M shares9.9%
Oct 13, 2026 · ↗ - Alta Partners LLCSCHEDULE 13G/A · passive (13G) · 200.0K shares4.9%
Oct 5, 2026 · ↗ - L1 Capital Global Opportunities Master Fund, Ltd.SCHEDULE 13G/A · passive (13G) · 111.5K shares5.0%
Aug 14, 2026 · ↗ - Intracoastal Capital LLCSCHEDULE 13G/A · passive (13G) · 235.7K shares10.0%
Aug 13, 2026 · ↗ - Daniel B. AsherSCHEDULE 13G/A · passive (13G) · 235.7K shares10.0%
Aug 13, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming Sunshine Biopharma Inc. as client
No lobbying filings found naming Sunshine Biopharma Inc. as the client.
Government Contracts
Federal awards to Sunshine Biopharma Inc. · USAspending
No federal contract awards found for Sunshine Biopharma Inc..
U.S. Patents
Recent USPTO applications naming Sunshine Biopharma Inc.
No USPTO patent applications found for Sunshine Biopharma Inc..
Annual Financials
From SBFM's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $36.3M | $34.9M | $24.1M | $4.3M | $228K |
| Operating income | -$6.2M | -$5.8M | -$4.8M | -$27.0M | -$2.4M |
| Net income | -$6.0M | -$5.1M | -$4.5M | -$26.7M | -$12.4M |
| Diluted EPS | n/a | -$7.32 | -$351.36 | -$1.76 | -$4.76 |
| Operating cash flow | -$5.3M | -$12.5M | -$8.8M | -$5.2M | -$1.8M |
| Cash and equivalents | n/a | n/a | n/a | $21.8M | $2.0M |
| Total assets | $30.1M | $30.6M | $27.3M | $29.2M | $2.2M |
| Total liabilities | $7.0M | $7.1M | $6.1M | $7.6M | $2.0M |
| Shareholders' equity | $23.0M | $23.5M | $21.2M | $21.6M | $212K |
As Sunshine Biopharma Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Apr 3, 2026 ↗
Stock Splits
Every split and reverse split in the price history
- 1-for-20Reverse splitOct 26, 2026
- 1-for-10Reverse splitJun 1, 2026
- 1-for-20Reverse splitAug 8, 2024
- 1-for-100Reverse splitApr 17, 2024
- 1-for-20Reverse splitFeb 1, 2019
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 5.07Shareholder voteOct 14, 2026
EDGAR ↗ - 8-K · Items 1.01, 8.01, 9.01Material agreement · Other eventsOct 9, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteSep 16, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsSep 11, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeAug 28, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsAug 3, 2026
EDGAR ↗ - 8-K · Items 1.01, 9.01Material agreementJul 20, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteMay 29, 2026
EDGAR ↗ - 8-K · Items 1.01, 8.01, 9.01Material agreement · Other eventsMay 19, 2026
EDGAR ↗
About Sunshine Biopharma Inc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersFORT LAUDERDALE, FL
IncorporatedCO
SEC CIK0001402328 ↗
Former namesSunshine Biopharma, Inc, Mountain West Business Solutions, Inc, mountain west business solutions,inc

